Worm-Based Diagnosis Combining Microfluidics toward Early Cancer Screening

Area of Science:

• Biotechnology
• Cancer Research
• Neuroscience

Background:

• Current cancer diagnostic methods like blood markers and endoscopy have limitations.
• There is a global need for reliable, non-invasive, and cost-effective cancer detection.
• Early cancer diagnosis significantly enhances treatment efficacy and reduces healthcare expenses.

Purpose of the Study:

• To review the advancements in early cancer diagnosis using the chemosensory system of *C. elegans*.
• To explore the integration of microfluidics technologies with *C. elegans*-based chemotaxis assays for improved cancer screening.

Main Methods:

• Detailed review of *C. elegans* chemotaxis assay procedures: synchronization, behavior assay, immobilization, and counting.
• Examination of microfluidics technologies enhancing automation, throughput, and efficiency in each assay step.
• Analysis of *C. elegans* diagnostic capabilities across various cancer types.

Main Results:

• The chemosensory neuronal system of *C. elegans* shows high sensitivity for early cancer detection.
• Microfluidics has demonstrated potential to automate and optimize *C. elegans*-based cancer screening protocols.
• Successful early diagnosis of multiple cancer types has been achieved using this worm-based approach.

Conclusions:

• Combining microfluidics with *C. elegans* chemotaxis assays offers a promising route for automated, non-invasive, and cost-effective early cancer screening.
• Further development and systematic integration of microfluidic modules are key to realizing a mature, large-scale cancer screening technology.